Wezenla

Wezenla (ustekinumab) is a prescription medication used to treat inflammatory conditions like psoriasis and psoriatic arthritis. It belongs to a class of drugs that modulate the immune system. This biologic therapy targets specific pathways to reduce inflammation and manage symptoms.

Wezenla (ustekinumab) is primarily used to treat moderate to severe plaque psoriasis in adults and children aged 6 and older. It is also approved for psoriatic arthritis, helping to reduce joint pain, swelling, and skin symptoms. The medication works by targeting specific proteins involved in inflammation, providing relief for chronic inflammatory conditions.

Many patients experience reduced redness, scaling, and thickness of psoriatic plaques after starting Wezenla. For psoriatic arthritis, it may help improve joint function and reduce morning stiffness. The medication is designed to target immune system pathways, which can lead to gradual symptom improvement over time.

Wezenla should be used under the guidance of a healthcare professional, especially for patients with a history of infections or tuberculosis. Regular monitoring may be required to assess response and safety. Patients should discuss their full medical history with their doctor before starting treatment.

Wezenla may interact with other immunosuppressants or live vaccines, potentially increasing infection risk. Combining it with certain medications could affect how the body processes the drug. Patients should inform their healthcare provider about all medications, including over-the-counter and herbal products, before starting Wezenla.